Organization and Principal Activities (Details Narrative) (10-Q) - USD ($) |
9 Months Ended | ||
|---|---|---|---|
Aug. 25, 2020 |
Sep. 30, 2020 |
Dec. 31, 2019 |
|
| Convertible notes payable | $ 849,576 | ||
| Liabilities | $ 872,687 | $ 910 | |
| Common shares | 500,000 | 500,000 | |
| Share Exchange Agreement [Member] | Sigyn Therapeutics, Inc [Member] | |||
| Percentage of acquisition ownership interest | 100.00% | ||
| Percentage of common stock outstanding | 75.00% | ||
| Debt tem | 1 year | ||
| Percentage of original issuer discount | 10.00% | ||
| Debt conversion price | $ 20 | ||
| Acquistion valuation cost | $ 12,500,000 | ||
| Warrant term | 5 years | ||
| Warrant price | $ 30 | ||
| Warrant valuation | $ 17,500,000 | ||
| Liabilities | $ 3,429,516 | $ 3,429,516 | |
| Common shares | 7,907,351 | 7,907,351 | |
| Share Exchange Agreement [Member] | Sigyn Therapeutics, Inc [Member] | Maximum [Member] | |||
| Convertible notes payable | $ 1,500,000 | ||
| Shareholders investment | $ 500,000 |
| X | ||||||||||
- Definition Percentage of common stock outstanding. No definition available.
|
| X | ||||||||||
- Definition Percentage of original issuer discount. No definition available.
|
| X | ||||||||||
- Definition Shareholders investment. No definition available.
|
| X | ||||||||||
- Definition Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition. No definition available.
|
| X | ||||||||||
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The price per share of the conversion feature embedded in the debt instrument. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. No definition available.
|
| X | ||||||||||
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|